Merck Agreement definition

Merck Agreement means that certain Development and License Agreement entered into by the Company and Merck KGaA on December 14, 1998, as amended and modified as of the date of this Agreement.

Merck Agreement means the Technology Transfer and License Agreement dated 26 July 1999 between Merck & Co. Inc. (“Merck”), Elan, Elan Pharmaceutical Research Corp. (now EDDI) and Elan Pharma International Limited.

Merck Agreement means that certain License and Research Collaboration Agreement dated as of April 25, 2014, by and between Merck and Seller Parent, as amended effective April 25, 2015, and February 6, 2017, and as may be further amended from time to time.

Examples of Merck Agreement in a sentence

• Under the Merck Agreement, the Company received a $30.0 million non-refundable, upfront payment in December 2014, and a one-time $20.0 million non-refundable milestone payment in February 2015 upon the initiation of the pivotal clinical trial using the current rVSV-ZEBOV GP vaccine product as one arm of the trial.

• Under the terms of the Merck Agreement, the Company granted Merck an exclusive, royalty bearing license to rVSV-ZEBOV GP and related technology.

• The royalty obligations under the Lumos Merck Agreement are on a product-by-product and country-by-country basis and will last until the later of expiration of the last licensed patent covering the product in such country and expiration of regulatory exclusivity for such product in such country.

• In November 2014, the Company entered into a licensing and collaboration agreement with Merck, or the Merck Agreement, to develop, manufacture and commercialize rVSV-ZEBOV GP, an Ebola vaccine the Company licensed from the Public Health Agency of Canada, or PHAC.

• On signature of this Agreement, the provisions of the Merck Agreement shall be terminated and replaced in their entirety with the terms and conditions set out below.

More Definitions of Merck Agreement

Merck Agreement means that certain License Agreement between TESARO and Merck, Sharp & Dohme Corp. (“Merck”), dated May 22, 2012, as amended from time to time.

Merck Agreement means that certain License and Collaboration Agreement by and among Intrexon, Ziopharm and Ares Trading S.A., a corporation organized and existing under the laws of Switzerland, having offices at Xxxx Xxxxxxxxxxxx xx X’Xxxxxxxxx, 0000 Xxxxxxx, Xxxxxxxxxxx (“Ares Trading”) effective March 27, 2015, as amended.

Merck Agreement means the Research Collaboration and License Agreement by and among Merck & Co., Inc., Transcell and Interneuron effective as of June 30, 1997, a copy of which is attached hereto as Appendix 1.2.

Merck Agreement means the License Agreement by and between Merck and Seller, dated February 3, 2017, as amended on April 27, 2017 and as may be further amended from time to time.

Merck Agreement means that certain License and Collaboration Agreement by and among Intrexon, Ziopharm and Ares Trading S.A., a corporation organized and existing under the laws of Switzerland, having offices at Zone Industrielle de L’Ouriettaz, 1170 Aubonne, Switzerland (“Ares Trading”) effective March 27, 2015, as amended. 1.54 “NDA” means a New Drug Application, as defined in the FD&C Act, as amended, and applicable regulations promulgated thereunder by the FDA. 1.55 “Neo-antigens” means [*****]. 1.56 “New Product Marks” has the meaning set forth in Section 6.5. 1.57 “NK Cells” means natural killer cells. 1.58 “NK Cells and Gamma Delta T Cell Products” means any pharmaceutical or biological product, process or therapy developed under or arising from the NK Cells and Gamma Delta T Cell Program, including all forms, formulations, presentations, doses, administrations and package configurations. 1.59 “NK Cells and Gamma Delta T Cell Program” means a program(s) of Research and Development focused on NK Cells and Gamma Delta T Cells. 1.60 “Non-Exclusive Products” means (a) NK Cells and Gamma Delta T Cell Products, and (b) TCR Non-Exclusive Products, in each case as generated or Developed by Alaunos. For clarity, Non-Exclusive Products include all forms, formulations, presentations, doses, administrations and package configurations thereof. 1.61 “Oncology” means the treatment or prevention of a human patient who has received a cancer diagnosis. 1.62 “Patents” means

Merck Agreement means the Clinical Trial Collaboration and Supply Agreement by and among Merck and Antigen Express made as of June 28, 2017 as the same may be amended from time to time in accordance with the terms thereof.

Merck Agreement means the Development and License Agreement, dated December 14, 1998, between the Company and Merck KgaA, as amended and modified as of the date of this Agreement. "NON-THIRD PARTY CHANGE OF CONTROL INJUNCTION" means any of the events referred to in paragraph (a) of Annex I that is not a Third Party Change of Control Injunction or an Antitrust Injunction.